Search

Your search keyword '"Musher, Benjamin L."' showing total 30 results
Start Over Author "Musher, Benjamin L."
30 results on '"Musher, Benjamin L."'

1. LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study

Author

Musher, Benjamin L, Rowinsky, Eric K, Smaglo, Brandon G, Abidi, Wasif, Othman, Mohamed, Patel, Kalpesh, Jawaid, Salmaan, Jing, James, Brisco, Amanda, Leen, Ann M, Wu, Mengfen, Sandin, Linda C, Wenthe, Jessica, Eriksson, Emma, Ullenhag, Gustav J, Grilley, Bambi, Leja-Jarblad, Justyna, Hilsenbeck, Susan G, Brenner, Malcolm K, and Loskog, Angelica S I

Published
2024
Full Text
View/download PDF

3. LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001) results from arm 1 of a non-randomised, single-centre, phase 1/2 study

Author

Musher, Benjamin L., Rowinsky, Eric K., Smaglo, Brandon G., Abidi, Wasif, Othman, Mohamed, Patel, Kalpesh, Jawaid, Salmaan, Jing, James, Brisco, Amanda, Leen, Ann M., Wu, Mengfen, Sandin, Linda C., Wenthe, Jessica, Eriksson, Emma, Ullenhag, Gustav J., Grilley, Bambi, Leja-Jarblad, Justyna, Hilsenbeck, Susan G., Brenner, Malcolm K., Loskog, Angelica, Musher, Benjamin L., Rowinsky, Eric K., Smaglo, Brandon G., Abidi, Wasif, Othman, Mohamed, Patel, Kalpesh, Jawaid, Salmaan, Jing, James, Brisco, Amanda, Leen, Ann M., Wu, Mengfen, Sandin, Linda C., Wenthe, Jessica, Eriksson, Emma, Ullenhag, Gustav J., Grilley, Bambi, Leja-Jarblad, Justyna, Hilsenbeck, Susan G., Brenner, Malcolm K., and Loskog, Angelica

Abstract

Background Pancreatic ductal adenocarcinoma is characterised by low immunogenicity and an immunosuppressive tumour microenvironment. LOAd703, an oncolytic adenovirus with transgenes encoding TMZ-CD40L and 4-1BBL, lyses cancer cells selectively, activates cytotoxic T cells, and induces tumour regression in preclinical models. The aim of this study was to evaluate the safety and feasibility of combining LOAd703 with chemotherapy for advanced pancreatic ductal adenocarcinoma. Methods LOKON001 was a non-randomised, phase 1/2 study conducted at the Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA, and consisted of two arms conducted sequentially; the results of arm 1 are presented here. In arm 1, patients 18 years or older with previously treated or treatment-naive unresectable or metastatic pancreatic ductal adenocarcinoma were treated with standard 28-day cycles of intravenous nab-paclitaxel 125 mg/m 2 plus gemcitabine 1000 mg/m 2 (up to 12 cycles) and intratumoural injections of LOAd703 every 2 weeks. Patients were assigned using Bayesian optimal interval design to receive 500 mu L of LOAd703 at 5 x 10 10 (dose 1), 1 x 10 11 (dose 2), or 5 x 10 11 (dose 3) viral particles per injection, injected endoscopically or percutaneously into the pancreatic tumour or a metastasis for six injections. The primary endpoints were safety and treatment-emergent immune response in patients who received at least one dose of LOAd703, and antitumour activity was a secondary endpoint. This study was registered with ClinicalTrials.gov, NCT02705196, arm 2 is ongoing and open to new participants. Findings Between Dec 2, 2016, and Oct 17, 2019, 23 patients were assessed for eligibility, leading to 22 patients being enrolled. One patient withdrew consent, resulting in 21 patients (13 [62%] men and eight [38%] women) assigned to a dose group (three to dose 1, four to dose 2, and 14 to dose 3). 21 patients were evaluable for safety. Median follow-up time was

Published
2024
Full Text
View/download PDF

6. Preoperative Treatment of Locally Advanced Rectal Cancer

Author

Schrag, Deborah, primary, Shi, Qian, additional, Weiser, Martin R., additional, Gollub, Marc J., additional, Saltz, Leonard B., additional, Musher, Benjamin L., additional, Goldberg, Joel, additional, Al Baghdadi, Tareq, additional, Goodman, Karyn A., additional, McWilliams, Robert R., additional, Farma, Jeffrey M., additional, George, Thomas J., additional, Kennecke, Hagen F., additional, Shergill, Ardaman, additional, Montemurro, Michael, additional, Nelson, Garth D., additional, Colgrove, Brian, additional, Gordon, Vallerie, additional, Venook, Alan P., additional, O’Reilly, Eileen M., additional, Meyerhardt, Jeffrey A., additional, Dueck, Amylou C., additional, Basch, Ethan, additional, Chang, George J., additional, and Mamon, Harvey J., additional

Published
2023
Full Text
View/download PDF

12. Abstract 867: Incidence of molecular alterations in KRAS and other known cancer genes in patients with pancreatic cancer assessed with a commercial genomic profiling panel compared to TCGA results

Author

Le, Alexander D., primary, Zhang, Bing, additional, Worley, Kim C., additional, Wheeler, David, additional, Musher, Benjamin L., additional, Dowst, Heidi, additional, Wood, Amy, additional, Schaeffer, Jeff, additional, Olsen, Nick, additional, Grego, Lorenzo, additional, Sonnleitner, Matt, additional, and Fisher, William E., additional

Published
2021
Full Text
View/download PDF

13. Evaluation of Circulating Tumor DNA for Methylated BCAT1 and IKZF1 to Detect Recurrence of Stage II/Stage III Colorectal Cancer (CRC)

Author

Musher, Benjamin L., primary, Melson, Joshua E., additional, Amato, Gianni, additional, Chan, David, additional, Hill, Marisa, additional, Khan, Iftekhar, additional, Kochuparambil, Samith T., additional, Lyons, Susan E., additional, Orsini, James, additional, Pedersen, Susanne K., additional, Robb, Bruce, additional, Saltzman, Joel, additional, Silinsky, Jennifer, additional, Gaur, Snigdha, additional, Tuck, Melissa K., additional, LaPointe, Lawrence C., additional, and Young, Graeme P., additional

Published
2020
Full Text
View/download PDF

14. Contagious acute gastrointestinal infections

Author

Musher, Daniel M. and Musher, Benjamin L.

Subjects
Gastrointestinal agents -- Research, Communicable diseases -- Causes of
Abstract

A study is conducted to examine contagion direct human-to-human spread of acute gastrointestinal illness, defined as a syndrome of vomiting, diarrhea that begins abruptly in healthy persons. Different ways of gathering, analyzing and presenting data has generated different estimates of the frequency of cute gastrointestinal illness, leading to contradictory results.

Published
2004

15. Clinical prediction of bacteremia and early antibiotics therapy in patients with solid tumors

Author

Hyak, Jonathan M., Al Mohajer, Mayar, Musher, Daniel M., and Musher, Benjamin L.

Abstract

AbstractObjective:To investigate the relationship between the systemic inflammatory response syndrome (SIRS), early antibiotic use, and bacteremia in solid-tumor patients.Design, setting, and participants:We conducted a retrospective observational study of adults with solid tumors admitted to a tertiary-care hospital through the emergency department over a 2-year period. Patients with neutropenic fever, organ transplant, trauma, or cardiopulmonary arrest were excluded.Methods:Rates of SIRS, bacteremia, and early antibiotics (initiation within 8 hours of presentation) were compared using the χ2and Student ttests. Binomial regression and receiver operator curves were analyzed to assess predictors of bacteremia and early antibiotics.Results:Early antibiotics were administered in 507 (37%) of 1,344 SIRS-positive cases and 492 (22%) of 2,236 SIRS-negative cases (P< .0001). Of SIRS-positive cases, 70% had blood cultures drawn within 48 hours and 19% were positive; among SIRS negative cases, 35% had cultures and 13% were positive (19% vs 13%; P =.003). Bacteremic cases were more often SIRS positive than nonbacteremic cases (60% vs 50%; P=.003), but they received early antibiotics at similar rates (50% vs 49%, P =.72). Three SIRS components predicted early antibiotics: temperature (OR, 1.7; 95% CI, 1.31–2.29; P =.0001), tachycardia (OR, 1.4; 95% CI, 1.10–1.69; P <.0001), and white blood-cell count (OR, 1.8; 95% CI, 1.56–2.14; P <.0001). Only temperature (OR, 1.6; 95% CI, 1.09–2.41; P =.01) and tachycardia (OR, 1.5; 95% CI, 1.09–2.06; P =.01) predicted bacteremia. SIRS criteria as a composite were poorly predictive of bacteremia (AUC, 0.57).Conclusions:SIRS criteria are frequently used to determine the need for early antibiotics, but they are poor predictors of bacteremia in solid-tumor patients. More reliable models are needed to guide judicious use of antibiotics in this population.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results